Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis.
J Microbiol Immunol Infect
; 54(5): 787-793, 2021 Oct.
Article
in English
| MEDLINE | ID: covidwho-1293986
ABSTRACT
OBJECTIVE:
We aimed to analyze clinical outcomes from patients with severe COVID-19 pneumonia that received either baricitinib plus dexamethasone or dexamethasone monotherapy.METHODOLOGY:
We performed a retrospective comparative study. Data from hospitalized patients with severe COVID-19 pneumonia (saturation <93%, bilateral pulmonary infiltrates) that were treated with baricitinib plus dexamethasone or dexamethasone were collected. Our primary objective was to compare overall mortality and secondly to compare progression to mechanical ventilation and over infection rates.RESULTS:
A total of 793 patients were assessed for inclusion criteria, 596 were excluded and 197 were analyzed for primaryoutcome:
123 in the baricitinib plus dexamethasone group and 74 in the dexamethasone monotherapy group. The mean age was 59.9 years (SD ± 14.5) and 62.1% (123/197) were male. 42.9% (85/197) of the cases required ICU admission and 25.8% (51/197) underwent invasive mechanical ventilation (IMV). Overall thirty-day mortality was 27.9% (55/197); Mortality was significantly lower in the baricitinib plus dexamethasone group compared to the dexamethasone monotherapy group (20.3% vs 40.5%, P = <.05). There was no difference in hospital acquired infections between both groups.CONCLUSION:
Thirty-day mortality was significantly lower in patients with COVID-19 pneumonia treated with baricitinib plus dexamethasone versus dexamethasone monotherapy. No difference was observed in progression to invasive mechanical ventilation and hospital acquired infections.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Purines
/
Pyrazoles
/
Sulfonamides
/
Azetidines
/
Dexamethasone
/
COVID-19 Drug Treatment
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
J Microbiol Immunol Infect
Journal subject:
Allergy and Immunology
/
Microbiology
Year:
2021
Document Type:
Article
Affiliation country:
J.jmii.2021.05.009
Similar
MEDLINE
...
LILACS
LIS